摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-Hydroxy-1,2,3,4-tetrahydroquinoline-5-carboxylic acid | 920739-82-8

中文名称
——
中文别名
——
英文名称
6-Hydroxy-1,2,3,4-tetrahydroquinoline-5-carboxylic acid
英文别名
——
6-Hydroxy-1,2,3,4-tetrahydroquinoline-5-carboxylic acid化学式
CAS
920739-82-8
化学式
C10H11NO3
mdl
——
分子量
193.2
InChiKey
OPCASZGKTYJQNS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    69.6
  • 氢给体数:
    3
  • 氢受体数:
    4

文献信息

  • Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
    申请人:Naccari Giancarlo
    公开号:US20090118357A1
    公开(公告)日:2009-05-07
    Therefore the present invention relates specifically to the compounds of general formula (I), in which R 1 and R 2 , which may be identical or different, are selected from the group comprising H, —C n H 2n-1 , a linear or branched alkyl group having from 1 to 6 carbon atoms, or together form an aromatic or aliphatic ring with 5 or 6 atoms; R 3 is selected from —CO—CH 3 , —NHOH, —OH, —OR 6 in which R 6 is a linear or branched alkyl group having from 1 to 6 carbon atoms; R 4 is selected from H, a linear or branched alkyl group having from 1 to 6 carbon atoms, phenyl, benzyl, —CF 3 or —CF 2 CF 3 , vinyl or allyl; R 5 , R 7 , R 8 are hydrogen atoms; or R 3 and R 4 , R 4 and R 5 , or R 7 and R 8 together form a ring, fused to the benzene, aromatic or aliphatic ring with 5 or 6 atoms comprising from 1 to 2 heteroatoms selected independently from the group comprising N, O, and use thereof in the medical field.
    因此,本发明特别涉及具有通用公式(I)的化合物,其中R1和R2,可以相同或不同,选自包括H,—CnH2n-1,具有1到6个碳原子的直链或支链烷基,或者共同形成一个含有5或6个原子的芳香族或脂肪族环;R3选自—CO—CH3,—NHOH,—OH,—OR6,其中R6是一个具有1到6个碳原子的直链或支链烷基;R4选自H,具有1到6个碳原子的直链或支链烷基,苯基,苄基,—CF3或—CF2CF3,乙烯基或烯丙基;R5,R7,R8是氢原子;或者R3和R4,R4和R5,或R7和R8共同形成一个环,与苯环,芳香族或脂肪族环融合,含有5或6个原子,并包括1到2个独立选自N,O的杂原子,及其在医疗领域的应用。
  • Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field
    申请人:Naccari Giancarlo
    公开号:US20120316230A1
    公开(公告)日:2012-12-13
    The present invention relates to compounds of formula (I), where R 1 and R 2 , which may be identical or different, are selected from the group comprising H, C n H 2n-1 , a linear or branched alkyl group having 1 to 6 carbons, or together form an aromatic or aliphatic ring with 5 or 6 atoms; R 3 is —CO—CH 3 , —NHOH, —OH, or —OR 6 where R 6 is a linear or branched alkyl group having 1 to 6 carbon atoms; R4 is H, linear or branched alkyl group having from 1 to 6 atoms, phenyl, benzyl, —CF 3 or CF 2 CF 3 , vinyl or allyl; R 5 , R 7 , R 8 are hydrogen atoms; or R 3 and R 4 , R 4 and R 5 , or R 7 and R 8 together form a ring, fused to the benzene, aromatic or aliphatic ring with 5 or 6 atoms comprising from 1 to 2 heteroatoms selected independently from the group comprising N, O, and use thereof in the medical field.
    本发明涉及式(I)的化合物,其中R1和R2,可以相同也可以不同,选择自H,CnH2n-1,具有1至6个碳的线性或支链烷基团,或者共同形成一个具有5或6个原子的芳香或脂肪环;R3为—CO—CH3,—NHOH,—OH或—OR6,其中R6为具有1至6个碳的线性或支链烷基团;R4为H,具有1至6个原子的线性或支链烷基团,苯基,苄基,—CF3或CF2CF3,乙烯基或丙烯基;R5,R7,R8为氢原子;或者R3和R4,R4和R5,或R7和R8共同形成一个环,与苯环,芳香或脂肪环共同构成一个具有1至2个杂原子的环,独立选择自N,O的群组;以及在医药领域中的应用。
  • COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD
    申请人:Giuliani International Limited
    公开号:EP1910275A2
    公开(公告)日:2008-04-16
  • PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS
    申请人:Giuliani International Limited
    公开号:EP2131829A1
    公开(公告)日:2009-12-16
  • COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE
    申请人:Baroni Sergio
    公开号:US20100305077A1
    公开(公告)日:2010-12-02
    In one aspect, the present invention relates to amino-salicylic-aminophenylpropionic compounds for the use in the treatment of the inflammatory component of the celiac disease. These compounds act by blocking the cytokines released in the celiac disease and are specifically useful in the treatment of cases refractory to the diet, in dietary errors and in the reduction of the celiac disease remission time.
查看更多